Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Dec 2022
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Chemotherapy-induced anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 16 Oct 2019 Results evaluating noninferiority of darbepoetin alfa versus placebo were published in the Journal of Thoracic Oncology
- 01 Jul 2019 According to European Clinical Trials Database record, trial is completed only in Belgium, Denmark and Slovenia (End Date: 05 Jun 2017) while prematurely ended at rest of locations.
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer